The optimal duration of adjuvant therapy in breast cancer: what kind of evidence? Chemotherapy: what kind of evidence?
Baldini, E.; Prochilo, T.
I Suppli di Tumori Official Journal of Societa Italiana di Cancerologia . 3(4): S79-S80
2004
ISSN/ISBN: 2283-5423 PMID: 15206221 Document Number: 568097
Document emailed within 1 workday
Related Documents
Robertson, D.W.; Bedell, R.; Lavery, J.V.; Upshur, R. 2002: What kind of evidence do we need to justify humanitarian medical aid? Lancet 360(9329): 330-333Shields, A.F. 2017: What is the optimal duration of adjuvant therapy in colon cancer? Clinical Advances in Hematology and Oncology: H&o 15(10): 734-738
Kadakia, K.C.; Worrilow, W.M.; Coley, H.; Salem, M.E. 2019: Optimal duration of adjuvant therapy for stage IIi colon cancer Clinical Advances in Hematology and Oncology: H&o 17(5): 289-298
Reynolds, T.M.; Wierzbicki, A.S. 2003: Does evidence-based medicine provide evidence? The evidence on breast cancer and the safety of oral contraceptives suggests that unorthodox interpretations may be just as valid Breast Journal 9(1): 66-67
Gamucci, T. 2004: The ATAC study on adjuvants in breast cancer. what kind of repercussions will it have on clinical practice? I Suppli di Tumori: Official Journal of Societa Italiana di Cancerologia . 3(4): S16
Abe, R.; Tsuchiya, A.; Koie, H.; Ono, K.; Abo, S.; Saito, K.; Tsukamoto, M.; Sato, T.; Mori, S.; Motoki, R. 1988: Cooperative research on post-operative adjuvant therapy of breast cancer. Tohoku Society of Adjuvant Chemo-endocrine Therapy of Breast Cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 15(9): 2707-2712
Donegan, W.L. 1992: Recent trends in the management of breast cancer. 3. Controversies in the use of adjuvant chemotherapy, hormonotherapy and radiotherapy for breast cancer Canadian Journal of Surgery. Journal Canadien de Chirurgie 35(4): 371-377
Liang, X.-f.; Ma, D.-c.; Ding, Z.-y.; Liu, Z.-z.; Guo, F.; Liu, L.; Yu, H.-y.; Han, Y.-l.; Xie, X.-d. 2013: Autologous cytokine-induced killer cells therapy on the quality of life of patients with breast cancer after adjuvant chemotherapy: a prospective study Zhonghua Zhong Liu Za Zhi 35(10): 764-768
Lucey, C.; Westphal, J.R. 1998: New approach to administrative medical decision-making: evidence-based medicine using high dose chemotherapy/bone marrow transplant for breast cancer Southern Medical Journal 91(2): 196-201
2006: Comparative effects of the administration period of adjuvant chemotherapy using doxifluridine (5'-DFUR) for 1 year versus 3 years after breast cancer surgery by the Shimane Breast Cancer Study Group Anticancer Research 26(1b): 591-597
Yoshida, M.; Saji, S.; Takagi, H.; Takeuchi, S.; Tsuda, H.; Nimura, Y.; Mizumoto, R.; Miyazaki, I.; Kobayashi, S.; Noguchi, M. 1993: A comparative study among ftorafur, ftorafur plus tamoxifen, and tamoxifen in adjuvant therapy for breast cancer. the Chubu Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer, Japan Gan to Kagaku Ryoho. Cancer and ChemoTherapy 20(15): 2325-2333
Kleber, F.X. 2000: Therapy with ACE inhibitors. what kind of risk make them indispensible? MMW Fortschritte der Medizin 142(46): 44-45
2004: Adjuvant chemotherapy for early breast cancer: protocol and nonprotocol treatment options. Proceedings of a national research leader think tank and 3 regional breast cancer update working group meetings. July-October 2003 Oncology 18(4 Suppl. 1): 5-22
Evans, R.A. 1995: Adjuvant chemotherapy in breast cancer New England Journal of Medicine 333(9): 596-597
Semiglazov, V.F.; Golubeva, O.M.; Bavli, I.L.; Ivanova, O.A.; Topuzov, E.E. 1992: The adjuvant chemotherapy of breast cancer Voprosy Onkologii 38(10): 1187-1194
Rouëssé, J.; May-Levin, F.; Sarrazin, D.; Petit, J.Y. 1978: Adjuvant chemotherapy of breast cancer La Revue du Praticien 28(13): 977-983
Kennedy, B.J. 1979: Adjuvant chemotherapy of breast cancer Minnesota Medicine 62(7): 509-511
Mattheiem, W.; Philippon, R.; Heuson, J.C. 1971: Adjuvant chemotherapy in breast cancer Acta Chirurgica Belgica Suppl 1: 105-111
Singhal, N.; Bapsy, P.P. 2003: Breast cancer and adjuvant chemotherapy National Medical Journal of India 16(4): 214-215
Fujii, M.; Sakabe, T.; Wakabayashi, K.; Kochi, M.; Mochizuki, F.; Kasakura, Y.; Yamagata, M.; Noro, M.; Osawa, T.; Iwai, S. 1994: The optimal period for orally administered fluoropyrimidines as an adjuvant chemotherapy for gastric cancer--a pilot study using 5-FU tablets compared with surgical operation alone Gan to Kagaku Ryoho. Cancer and ChemoTherapy 21(8): 1199-1208